Growth surprised, but risk still matters
- Oscar is now a pure play on individual ACA health insurance after leaving Medicare Advantage and Small Group plans.
- Membership rose 56% year over year to about 3.2 million at March 31, 2026, which broke the prior shrinkage fear.
- Q1 2026 net income was $679 million, helped by a 70.5% medical loss ratio and a 15.2% SG&A ratio.
- The main weakness is that risk adjustment, the ACA system that moves money between insurers based on member sickness, can swing earnings hard.
- The valuation score is only middling, so the stock needs proof that Q1 growth can last beyond open enrollment.
A better story, not a clean one
Oscar's Q1 2026 report changed the debate. The market expected pressure after enhanced ACA premium tax credits expired at the end of 2025. Instead, membership rose 56% year over year to about 3.2 million at March 31, 2026.
That growth mattered because the cost base spread across more members. Oscar reported a 70.5% medical loss ratio, which means medical costs took 70.5 cents of each premium dollar. It also reported a 15.2% SG&A ratio, showing more scale in selling and overhead.
The bull case is now simple: Oscar may have a real consumer brand in ACA plans, and its software-heavy model can turn growth into profit. Q1 2026 net income was $679 million, a sharp contrast with the $443 million net loss in 2025.
The bear case did not vanish. The same ACA system that helped growth can also hurt it. Subsidy changes, stricter checks on who can enroll, risk adjustment swings, and possible tariffs on drugs and medical supplies could all pressure the next few quarters.
Premiums pay the bills
Oscar makes almost all of its money from premiums on individual and family health plans sold through federal and state ACA exchanges. In Q1 2026, premium revenue was $4.58 billion out of $4.65 billion of total revenue.
The company says its edge is a full stack technology platform. In plain English, that means Oscar built much of the software used to sell plans, manage members, handle claims, and point people toward care.
+Oscar is the smaller services side. It uses Oscar's platform for other health care groups. The bigger strategic move is ICHRA, a benefit model where employers give workers money to buy their own individual plan. Oscar bought Lucie, IHC Specialty Benefits, and Healthinsurance.org in 2025 to build around that market.
Where it breaks is medical cost math. Oscar must price plans before it knows exactly how sick its members and competitors' members are. In 2025, adverse risk adjustment accruals helped push the company from a first full-year profit in 2024 to a $443 million net loss.
Built around ACA shoppers
Individual ACA health plans
This is Oscar's core product and main source of revenue. Plans are sold to individuals and families on ACA exchanges.
ICHRA-focused marketplace tools
Oscar wants to serve workers whose employers fund individual coverage through an Individual Coverage Health Reimbursement Arrangement. The 2025 deals support that push.
Lucie direct enrollment platform
Lucie adds direct enrollment technology. That can help Oscar control more of the shopping and signup path.
IHC Specialty Benefits brokerage
IHC adds brokerage services for individual and supplemental products. This gives Oscar more ways to reach customers outside its own carrier channel.
Healthinsurance.org
Healthinsurance.org is a consumer education website. It can bring in shoppers who are trying to understand health insurance before they buy.
+Oscar
+Oscar provides technology and administrative services to other health care entities. It is strategically useful, but premium insurance remains the main business.
One segment, premium-heavy revenue
Oscar reports as one operating segment. The mix shown uses Q1 2026 revenue lines, because the company does not disclose multiple operating segment shares.
What could go wrong
Risk adjustment miss
High impact · High oddsRisk adjustment is the ACA process that shifts money between insurers based on how sick members are. Oscar's 2025 loss showed how painful a wrong estimate can be. A larger member base could make the dollar impact bigger if the model is wrong again.
Subsidy and enrollment squeeze
High impact · Medium oddsEnhanced ACA premium tax credits expired at the end of 2025. Oscar still grew fast in Q1 2026, but management also said coverage became unaffordable for some people after open enrollment. The One Big Beautiful Bill Act and program integrity rules could further reduce marketplace participation.
Q1 growth fades
High impact · Medium oddsThe 56% membership jump changed the story, but it may not all stick. New members can leave, fail to pay premiums, or carry different medical costs than expected. If membership falls while costs stay high, the operating leverage case weakens.
Medical supply tariff shock
Medium impact · Medium oddsOscar added a risk in Q1 2026 about possible tariffs on pharmaceutical products, ingredients, medical devices, and supplies. Oscar does not make these products, but higher provider and drug costs can flow into claims. That would pressure the medical loss ratio.
ACA concentration
Medium impact · High oddsOscar exited Medicare Advantage and Small Group plans, leaving it fully focused on the Individual market. Focus can improve execution, but it also ties the company to one policy and pricing system. A state-level pricing mistake or rule change can matter more when there are few other lines to offset it.
In one breath
What does Oscar Health do?
Oscar sells health insurance plans to individuals and families, mainly through ACA exchanges. It also uses its software platform for services and is building tools for the ICHRA market.
Is Oscar Health profitable?
Oscar reached its first full-year net income in 2024, then lost $443 million in 2025. In Q1 2026, it reported net income of $679 million, so profitability is improving but still volatile.
Why is risk adjustment important for Oscar?
Risk adjustment moves money among ACA insurers based on how sick their members are. Oscar must estimate this before all data is known, and bad estimates hurt 2025 results.
What should investors watch next?
The key signals are Q2 and Q3 membership, MLR, SG&A ratio, and risk adjustment updates. Investors should also watch whether tariff risks or ACA rule changes raise medical costs or reduce enrollment.